Subscribe
shutterstock_2026137224_flowersandtraveling
Flowersandtraveling / Shutterstock.com
18 November 2021Big PharmaAlex Baldwin

Pfizer signs antiviral COVID-19 licence with MPP

Pfizer is the latest pharmaceutical company to sign a licensing agreement with the Medicines Patent Pool (MPP) to help increase access to its COVID-19 oral antiviral treatment candidate PAXLOVID (PF-07321332) for low and middle-income countries.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pfizer claims employee stole COVID-19 vaccine documents
25 November 2021   Pfizer is currently investigating a soon-to-be former employee who it believes has transferred more than 12,000 files, many of which contain confidential and trade secret information, to her personal devices and has repeatedly attempted to cover her tracks.
Americas
BMS, Pfizer win patent dispute over blockbuster drug, Eliquis
6 September 2021   In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.
Big Pharma
Pfizer drops Xeljanz patent suits
20 April 2021   Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Pfizer claims employee stole COVID-19 vaccine documents
25 November 2021   Pfizer is currently investigating a soon-to-be former employee who it believes has transferred more than 12,000 files, many of which contain confidential and trade secret information, to her personal devices and has repeatedly attempted to cover her tracks.
Americas
BMS, Pfizer win patent dispute over blockbuster drug, Eliquis
6 September 2021   In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.
Big Pharma
Pfizer drops Xeljanz patent suits
20 April 2021   Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.

More on this story

Americas
Pfizer claims employee stole COVID-19 vaccine documents
25 November 2021   Pfizer is currently investigating a soon-to-be former employee who it believes has transferred more than 12,000 files, many of which contain confidential and trade secret information, to her personal devices and has repeatedly attempted to cover her tracks.
Americas
BMS, Pfizer win patent dispute over blockbuster drug, Eliquis
6 September 2021   In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.
Big Pharma
Pfizer drops Xeljanz patent suits
20 April 2021   Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB